As we reported July 3, a Henry Ford Health System retrospective found a significant reduction in death for those treated with hydroxychloroquine over a non-treated group. Another recent study, not yet peer reviewed, is found on PrePrints. Published online July 3 and titled, “COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study,” the paper looks at 141 severe COVID-19 patients who received “the triple therapy”: zinc, low-dose HCQ, and azithromycin. Findings included that 2.8% of the treated group were hospitalized, compared with 15.4% for the control group. The Conclusion notes that “treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.”
CNN Cast Doubts: Political Hot Piece or Fair Critique?
In a July 2 article CNN say that while, “A surprising new study [Henry Ford] found the controversial antimalarial drug hydroxychloroquine helped patients better survive,” “the findings, like the federal government’s use of the drug itself, were disputed.” They note that many other studies have found no benefit and also negative cardiac events. FDA’s EUA was pulled, and many trials around the globe were halted. Method problems in the Ford study were pointed out: concurrent steroid use could account for the findings, and persons with heart problems were screened out. Other issues are raised, and an expert tells CNN, “There’s a little bit of loosey-goosiness here in all this.” As an afterthought, CNN notes that Tumps’s trade advisor Peter Navarro has praised the Henry Ford team study. In sum, CNN notes legitimate concerns about HCQ research. Yet, with that network’s constant anti-Trump content in mind, perhaps we acted too early in pulling the plug on widespread HCQ research and treatment. Is that a possibility?